Fundz

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Aug 01, 2024

Contract Type

partnership

United StatesBiotechnologyHealthcareHealth CareGeneticsTherapeutics

Description

Passage Bio, Inc. has out-licensed its three clinical-stage pediatric lysosomal storage disease programs to GEMMA Biotherapeutics, Inc. and entered a new strategic research and collaboration agreement to advance genetic medicines for CNS indications, extending the operating cash runway to the end of Q2 2026.

Company Information

Company

Passage Bio

Location

United States

About

Passage Bio, Inc. (NASDAQ: PASG) is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases.

Related People

Will
Senior decision-maker at this company
••••••••@••••••••

See Will's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Passage Bio's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Passage Bio signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.